Very High

Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality

Previous studies have shown reduced cardiovascular risk with increasing high-density lipoprotein cholesterol (HDL-C) levels. However, recent data in the general population have shown increased risk of adverse outcomes at very high concentrations of HDL-C. Thus, we aimed to study the gender-specific relation between very high HDL-C levels (>80,>100 mg/100 ml) and adverse cardiovascular outcomes and the genetic basis in the general population enrolled in the United Kingdom Biobank. A total of 415,416 participants enrolled in the United Kingdom Biobank without coronary artery disease were include...

Remdesivir found to reduce need for mechanical ventilation in patients hospitalised with COVID-...

Remdesivir in addition to standard of care, compared with standard of care alone, reduced the need f...

Study finds functional recovery and coronary outcomes are good in multisystem inflammatory synd...

Findings from a study published in the Journal of the American Heart Association suggest that functi...


Suggested videos

Search:
Date
Filters:
Highlights
10:33

Highlights of the San Antonio Breast Cancer Symposium 2021

Presenter: Virginia G. Kaklamani
Oncology : Breast Cancer
SABCS 2021
Novelties
8:35

Novelties in the treatment of myelofibrosis and polycythemia vera 2021

Presenter: Srdan Verstovsek
Hematology
ASH 2021
Risks for
5:01

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology

Presenter: Lisa K. Hicks
Hematology
ASH 2021
Novelties
12:44

Novelties in the treatment of multiple myeloma 2021

Presenter: Andrzej Jakubowiak
Hematology
ASH 2021
Antibody R
7:02

Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms

Presenter: Susanne Saussele
Hematology
ASH 2021
Correlativ
4:24

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies

Presenter: Lisa A. Carey
Oncology : Breast Cancer
SABCS 2021
Novelties
12:54

Novelties on the treatment of non-Hodgkin lymphoma 2021

Presenter: Umberto Vitolo
Hematology
ASH 2021
Results fr
8:57

Results from the Randomized Phase 3 Transform Study

Presenter: Manali Kamdar
Hematology
ASH 2021
Final resu
5:20

Final results of KEYNOTE-355

Presenter: Javier Cortes
Oncology : Breast Cancer
SABCS 2021
PALLAS tri
8:41

PALLAS trial: Adjuvant palbociclib in HR+/HER2- early breast cancer

Presenter: Michael Gnant
Oncology : Breast Cancer
SABCS 2021
The DESTIN
5:07

The DESTINY-Breast03 trial

Presenter: Sara Hurvitz
Oncology : Breast Cancer
SABCS 2021
Associatio
2:59

Associations of hypoglycaemia and glycaemic variability with cardiac arrhythmias using a long-term monitoring approach in insulin-treated patients with type 2 diabetes

Presenter: Andreas Andersen
Diabetology : Diabetes
EASD 2021
The role o
4:35

The role of SGLT2 inhibitors in the treatment of diabetes with cardiovascular disease

Presenter: Mikael Rydén
Diabetology : Diabetes
EASD 2021
The curren
14:50

The current issues in Hypoglycaemia

Presenter: Brian Frier
Diabetology : Diabetes
EASD 2021
Current gu
12:05

Current guidelines on diabetes management

Presenter: Christoph Wanner
Diabetology : Diabetes
EASD 2021
Spotlight
16:53

Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)

Presenter: Peter Galle
Oncology
ESMO 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Diagnostic
10:55

Diagnostic delay in pulmonary arterial hypertension

Presenter: Barbro Kjellström and Bodil Ivarsson
Clinical I
6:21

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Babak Dehestani
Internal Medicine
Associatio
20:17

Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events

Presenter: Michael Camilleri
Internal Medicine
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology
The role o
10:22

The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction

Presenter: Michael A. Nauck
Cardiology , Diabetology
Clinical I
9:00

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Alexander Miras
Cardiology , Diabetology